The effect of naloxone-3-glucuronide on colonic transit time in healthy men after acute morphine administration: A placebo-controlled double-blinded crossover preclinical volunteer study

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 11-12, 2008, Pages 1334-1341

  Netzer, P ^a,b,d   Sendensky, A ^a   Wissmeyer, M P ^a   Baumeler, S ^a   Batista, C ^c   Scheurer, U ^a   Krause, T ^a   Reber, P ^b   Brenneisen, R ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b Lindenhofspital   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d GI Unit   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MORPHINE; NALOXONE; NALOXONE 3 GLUCURONIDE; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; COLON MOTILITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; MALE; NORMAL HUMAN; PAIN THRESHOLD; PERISTALSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; SYSTEMIC CIRCULATION; VOLUNTEER; VOMITING;

ADULT; ANALGESICS, OPIOID; COLON; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GASTROINTESTINAL TRANSIT; HUMANS; INDIUM RADIOISOTOPES; MALE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; SENSORY THRESHOLDS; YOUNG ADULT;

EID: 55349115730     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03855.x     Document Type: Article

References (34)

1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001 182 : S11 8.
2. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003 63 : 649 71.
3. Choi Y, Billings J. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 2002 24 : 71 90.
4. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002 23 : 48 53.
5. Plaisance L, Ellis JA. Opioid-induced constipation. Management is necessary but prevention is better. Am J Nurs 2002 102 : 72 3.
6. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000 84 : 105 9.
7. Tofil NM, Benner KW, Faro SJ, Winkler MK. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Pediatr Crit Care Med 2006 7 : 252 4.
8. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992 52 : 90 5.
9. Neary P, Delaney CP. Alvimopan. Expert Opin Investig Drugs 2005 14 : 479 88.
10. Hawkes ND, Richardson C, Evans BK, Rhodes J, Lewis SJ, Thomas GAO. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther 2001 15 : 625 30.
11. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997 41 : 116 22.
12. Ulens C, Baker L, Ratka A, Waumans D, Tytgat J. Morphine-6beta- glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 2001 62 : 1273 82.
13. Reber P, Brenneisen R, Flogerzi B, Batista C, Netzer P, Scheurer U. Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine. Dig Dis Sci 2007 52 : 502 7.
14. Curatolo M, Petersen-Felix S, Gerber A, rendt-Nielsen L. Remifentanil inhibits muscular more than cutaneous pain in humans. Br J Anaesth 2000 85 : 529 32.
15. Brennum J, Kjeldsen M, Jensen K, Jensen TS. Measurements of human pressure-pain thresholds on fingers and toes. Pain 1989 38 : 211 7.
16. Luginbuhl M, Gerber A, Schnider TW, Petersen-Felix S, rendt-Nielsen L, Curatolo M. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg 2003 96 : 726 32.
17. Reber PU, Netzer P, Gaia C, et al. Influence of naloxone on gastric emptying of solid meals, myoelectrical gastric activity and blood hormone levels in young healthy volunteers. Neurogastroenterol Motil 2002 14 : 487 93.
18. Netzer P, Gaia C, Lourens ST, et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers. Aliment Pharmacol Ther 2002 16 : 119 27.
19. Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989 257 : G284 90.
20. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992 103 : 36 42.
21. Proano M, Camilleri M, Phillips SF, Brown ML, Thomforde GM. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990 258 : G856 62.
22. Proano M, Camilleri M, Phillips SF, Thomforde GM, Brown ML, Tucker RL. Unprepared human colon does not discriminate between solids and liquids. Am J Physiol 1991 260 : G13 6.
23. Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991 101 : 107 15.
24. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999 94 : 351 7.
25. Petersen-Felix S, Luginbuhl M, Schnider TW, Curatolo M, rendt-Nielsen L, Zbinden AM. Comparison of the analgesic potency of xenon and nitrous oxide in humans evaluated by experimental pain. Br J Anaesth 1998 81 : 742 7.
26. O'Connor MK, ed. The Mayo Clinic Manual of Nuclear Medicine. New York : Churchill Livingstone, 1996.
27. Cassel JA, Daubert JD, DeHaven RN. [3H]Alvimopan binding to the [mu] opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol 2005 520 : 29 36.
28. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996 59 : 469 75.
29. Taguchi A, Sharma N, Saleem RM, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001 345 : 935 40.
30. Yuan CS, Israel RJ. Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006 15 : 541 52.
31. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000 283 : 367 72.
32. Yuan CS, Wei G, Foss JF, O'Connor M, Karrison T, Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002 300 : 118 23.
33. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005 17 : 157 65.
34. Tan EK, Cornish J, Darzi AW, Tekkis PP. Meta-analysis: alvimopan vs. placebo in the treatment of post-operative ileus. Aliment Pharmacol Ther 2007 25 : 47 57.